JP2019527718A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019527718A5 JP2019527718A5 JP2019507303A JP2019507303A JP2019527718A5 JP 2019527718 A5 JP2019527718 A5 JP 2019527718A5 JP 2019507303 A JP2019507303 A JP 2019507303A JP 2019507303 A JP2019507303 A JP 2019507303A JP 2019527718 A5 JP2019527718 A5 JP 2019527718A5
- Authority
- JP
- Japan
- Prior art keywords
- compound according
- independently
- heteroatoms
- sulfur
- nitrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 22
- 150000001875 compounds Chemical class 0.000 claims 22
- 229910052717 sulfur Inorganic materials 0.000 claims 15
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 11
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 11
- 125000005842 heteroatom Chemical group 0.000 claims 11
- 229910052757 nitrogen Inorganic materials 0.000 claims 11
- 229910052760 oxygen Inorganic materials 0.000 claims 11
- 239000001301 oxygen Substances 0.000 claims 11
- 239000011593 sulfur Substances 0.000 claims 11
- 150000003839 salts Chemical class 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- -1 pyridadinyl Chemical group 0.000 claims 5
- 125000003118 aryl group Chemical group 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 125000001931 aliphatic group Chemical group 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 125000000623 heterocyclic group Chemical group 0.000 claims 3
- 229920006395 saturated elastomer Polymers 0.000 claims 3
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 claims 2
- 102100039390 Toll-like receptor 7 Human genes 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 208000007815 Acquired Hyperostosis Syndrome Diseases 0.000 claims 1
- 208000026326 Adult-onset Still disease Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000005024 Castleman disease Diseases 0.000 claims 1
- 206010008690 Chondrocalcinosis pyrophosphate Diseases 0.000 claims 1
- 208000015943 Coeliac disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 201000005569 Gout Diseases 0.000 claims 1
- 102100026018 Interleukin-1 receptor antagonist protein Human genes 0.000 claims 1
- 101710144554 Interleukin-1 receptor antagonist protein Proteins 0.000 claims 1
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 1
- 208000005777 Lupus Nephritis Diseases 0.000 claims 1
- 102100022691 NACHT, LRR and PYD domains-containing protein 3 Human genes 0.000 claims 1
- 101710126825 NACHT, LRR and PYD domains-containing protein 3 Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 201000004854 SAPHO syndrome Diseases 0.000 claims 1
- 201000010848 Schnitzler Syndrome Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000012472 biological sample Substances 0.000 claims 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 208000002849 chondrocalcinosis Diseases 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 208000028774 intestinal disease Diseases 0.000 claims 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims 1
- 230000000737 periodic effect Effects 0.000 claims 1
- 208000025487 periodic fever syndrome Diseases 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 201000003068 rheumatic fever Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 125000004306 triazinyl group Chemical group 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662371917P | 2016-08-08 | 2016-08-08 | |
| US62/371,917 | 2016-08-08 | ||
| PCT/US2017/045671 WO2018031434A1 (en) | 2016-08-08 | 2017-08-07 | Tlr7/8 antagonists and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019527718A JP2019527718A (ja) | 2019-10-03 |
| JP2019527718A5 true JP2019527718A5 (https=) | 2020-09-17 |
| JP7125385B2 JP7125385B2 (ja) | 2022-08-24 |
Family
ID=59656207
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019507303A Active JP7125385B2 (ja) | 2016-08-08 | 2017-08-07 | Ｔｌｒ７／８アンタゴニストおよびそれらの使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US10947214B2 (https=) |
| EP (2) | EP3497094B1 (https=) |
| JP (1) | JP7125385B2 (https=) |
| KR (2) | KR102942565B1 (https=) |
| CN (1) | CN109563075B (https=) |
| AU (1) | AU2017311047B2 (https=) |
| DK (1) | DK3497094T3 (https=) |
| ES (1) | ES2944573T3 (https=) |
| IL (1) | IL264676B (https=) |
| MX (1) | MX390698B (https=) |
| RU (1) | RU2758686C2 (https=) |
| SG (1) | SG11201900947RA (https=) |
| WO (1) | WO2018031434A1 (https=) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3005766A1 (en) | 2015-12-17 | 2017-06-22 | Merck Patent Gmbh | Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders |
| JP7125385B2 (ja) * | 2016-08-08 | 2022-08-24 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｔｌｒ７／８アンタゴニストおよびそれらの使用 |
| IL265921B2 (en) | 2016-10-14 | 2024-05-01 | Prec Biosciences Inc | Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome |
| US11370794B2 (en) * | 2016-11-11 | 2022-06-28 | Dynavax Technologies Corporation | Toll-like receptor antagonist compounds and methods of use |
| SG11202005547YA (en) | 2017-12-19 | 2020-07-29 | Merck Patent Gmbh | Tlr7/8 antagonists and uses thereof |
| US10966999B2 (en) | 2017-12-20 | 2021-04-06 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| CN111511754B (zh) | 2017-12-20 | 2023-09-12 | 捷克共和国有机化学与生物化学研究所 | 活化sting转接蛋白的具有膦酸酯键的2’3’环状二核苷酸 |
| JP7328977B2 (ja) | 2018-02-12 | 2023-08-17 | エフ． ホフマン－ラ ロシュ アーゲー | ウイルス感染の処置および予防のための新規のスルホン化合物および誘導体 |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| TW201945388A (zh) | 2018-04-12 | 2019-12-01 | 美商精密生物科學公司 | 對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶 |
| EP3802539B1 (en) * | 2018-06-05 | 2023-09-20 | F. Hoffmann-La Roche AG | Tetrahydro-1h-pyrazino[2,1-a]isoindolylquinoline compounds for the treatment of autoimmune disease |
| EP3807270B1 (en) | 2018-06-12 | 2023-09-13 | F. Hoffmann-La Roche AG | Novel heteroaryl heterocyclyl compounds for the treatment of autoimmune disease |
| CN112584903B (zh) * | 2018-07-23 | 2025-12-23 | 豪夫迈·罗氏有限公司 | 用于自身免疫性疾病治疗的哌嗪化合物 |
| EP3847169A1 (en) | 2018-09-04 | 2021-07-14 | F. Hoffmann-La Roche AG | Benzothiazole compounds for the treatment of autoimmune diseases |
| US11548884B2 (en) | 2018-09-06 | 2023-01-10 | Hoffmann-La Roche Inc. | Cyclic amidine compounds for the treatment of autoimmune disease |
| EP3847173B1 (en) | 2018-09-06 | 2023-04-12 | F. Hoffmann-La Roche AG | Novel pyrazolopyridine compounds for the treatment of autoimmune disease |
| JP7530360B2 (ja) * | 2018-11-30 | 2024-08-07 | 武田薬品工業株式会社 | Ｔｙｋ２阻害剤およびその使用 |
| WO2021084022A1 (en) | 2019-10-31 | 2021-05-06 | F. Hoffmann-La Roche Ag | Hydropyrazino[1,2-d][1,4]diazepine compounds for the treatment of autoimmune disease |
| US12503471B2 (en) | 2019-11-19 | 2025-12-23 | Hoffmann-La Roche Inc. | Triazatricycle compounds for the treatment of autoimmune disease |
| CN114728976B (zh) * | 2019-11-19 | 2024-08-16 | 豪夫迈·罗氏有限公司 | 用于治疗自身免疫性疾病的氢-1H-吡咯并[1,2-a]吡嗪化合物 |
| WO2021099406A1 (en) | 2019-11-20 | 2021-05-27 | F. Hoffmann-La Roche Ag | Spiro(isobenzofuranazetidine) compounds for the treatment of autoimmune disease |
| WO2021110614A1 (en) * | 2019-12-03 | 2021-06-10 | F. Hoffmann-La Roche Ag | HYDROPYRIDO[1,2-α]PYRAZINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE |
| US12410418B2 (en) | 2019-12-06 | 2025-09-09 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome |
| EP4216949A4 (en) * | 2020-09-28 | 2024-12-11 | Yale University | Selective agonists of 5-ht2a receptor and methods of use |
| CR20230478A (es) | 2021-04-16 | 2023-11-30 | Gilead Sciences Inc | Compuestos de tienopirrol. |
| KR20240056747A (ko) | 2021-09-10 | 2024-04-30 | 길리애드 사이언시즈, 인코포레이티드 | 티에노피롤 화합물 |
| CN115073369A (zh) * | 2022-05-31 | 2022-09-20 | 汉瑞药业(荆门)有限公司 | 一种5-溴喹啉-8-甲醛的制备方法 |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE812911C (de) * | 1945-03-12 | 1951-09-06 | Rhone Poulenc Sa | Verfahren zur Herstellung von neuen substituierten Derivaten des Piperidins |
| CH578535A5 (en) * | 1973-05-11 | 1976-08-13 | Ciba Geigy Ag | Quinoline-3-carboxylic acid derivs - with e.g. analgesic, antinociceptive, antiinflammatory and antiallergic props |
| US4933447A (en) | 1987-09-24 | 1990-06-12 | Ss Pharmaceutical Co., Ltd. | Quinoline derivatives |
| FR2798656B1 (fr) | 1999-09-17 | 2004-12-17 | Aventis Pharma Sa | Derives de la quinolyl propyl piperidine, leur preparation et les compositions qui les contiennent |
| PL369674A1 (en) | 2001-11-14 | 2005-05-02 | Merck Patent Gmbh | Pyrazole derivatives as psychopharmaceuticals |
| GB0206033D0 (en) * | 2002-03-14 | 2002-04-24 | Pfizer Ltd | Compounds useful in therapy |
| WO2003105850A1 (en) * | 2002-06-18 | 2003-12-24 | Abbott Laboratories | 2-aminoquinolines as melanin concentrating hormone receptor antagonists |
| BR0313405A (pt) | 2002-08-12 | 2005-07-12 | Takeda Pharmaceutical | Compostos, métodos para preparar um composto e para prevenir e/ou tratar câncer, prodroga, medicamento, modulador do receptor de androgênio, agente para prevenir e/ou tratar hipogonadismo ou pertubação climatérica masculina, osteoporose e câncer, e, uso de um composto |
| MXPA05005111A (es) * | 2002-11-12 | 2005-07-01 | Pfizer Prod Inc | Derivados de quinolina. |
| GB0227240D0 (en) | 2002-11-21 | 2002-12-31 | Glaxo Group Ltd | Compounds |
| US20050124625A1 (en) | 2003-10-21 | 2005-06-09 | Salvati Mark E. | Piperazine derivatives and their use as modulators of nuclear hormone receptor function |
| US20070225308A1 (en) * | 2004-03-15 | 2007-09-27 | Kyowa Hakko Kogyo Co.,Ltd. | 2-Amino Quinazoline Derivative |
| US20060211752A1 (en) | 2004-03-16 | 2006-09-21 | Kohn Leonard D | Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression |
| US20070004679A1 (en) | 2004-05-17 | 2007-01-04 | Nathalie Schlienger | Androgen receptor modulators and methods of treating disease using the same |
| CA2566942A1 (en) | 2004-05-17 | 2005-12-08 | Acadia Pharmaceuticals Inc. | Androgen receptor modulators and method of treating disease using the same |
| WO2006009245A1 (ja) | 2004-07-23 | 2006-01-26 | Tanabe Seiyaku Co., Ltd. | 含窒素縮合二環式化合物 |
| GB0510810D0 (en) * | 2005-05-26 | 2005-06-29 | Novartis Ag | Organic compounds |
| GB0526042D0 (en) * | 2005-12-21 | 2006-02-01 | Syngenta Participations Ag | Chemical compounds |
| EP1987827A1 (en) | 2006-02-20 | 2008-11-05 | Takeda Pharmaceutical Company Limited | Novel pharmaceutical |
| EP1903038A1 (de) | 2006-09-07 | 2008-03-26 | Bayer Schering Pharma Aktiengesellschaft | N-(1-Hetaryl-piperidin-4-yl)-(het)arylamide als EP2-Rezeptor Modulatoren |
| JP2010504367A (ja) * | 2006-09-26 | 2010-02-12 | グラクソ グループ リミテッド | 性機能障害、認知障害、精神病性障害、不安、鬱病などを処置するための５ｈｔ１ａ受容体モジュレーターとしての５−｛２−［４−（２−メチル−５−キノリニル）−ｌ−ピペリジニル］エチル｝キノリノン誘導体 |
| CL2008001002A1 (es) | 2007-04-11 | 2008-10-17 | Actelion Pharmaceuticals Ltd | Compuestos derivados de oxazolidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para preparar un medicamento para tratar una infeccion bacteriana. |
| CA2689985C (en) * | 2007-06-05 | 2015-07-14 | Sanofi-Aventis | Di(hetero)arylcyclohexane derivatives, their preparation, their use and pharmaceutical compositions comprising them |
| WO2009140200A1 (en) * | 2008-05-12 | 2009-11-19 | Amnestix, Inc. | Compounds for improving learning and memory |
| CN102143746A (zh) | 2008-07-03 | 2011-08-03 | 埃克塞利希斯股份有限公司 | Cdk 调节剂 |
| WO2010026121A1 (en) | 2008-09-02 | 2010-03-11 | Novartis Ag | Bicyclic kinase inhibitors |
| WO2010063352A1 (en) | 2008-12-01 | 2010-06-10 | Merck Patent Gmbh | 2, 5-diamino-substituted pyrido [4, 3-d] pyrimidines as autotaxin inhibitors against cancer |
| KR20110117705A (ko) | 2009-02-11 | 2011-10-27 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 톨-유사 수용체 조정제 및 질병의 치료 |
| EP2401275B1 (en) | 2009-02-24 | 2013-07-24 | Respiratorius AB | Naphthyridine derivatives having bronchodilating activity |
| JP5864417B2 (ja) | 2009-07-16 | 2016-02-17 | マリンクロッド エルエルシー | トール様受容体９のアンタゴニストとしての（＋）−モルフィナンおよびその治療的使用 |
| US20120214803A1 (en) | 2011-02-18 | 2012-08-23 | Vifor (International) Ag | Novel Sulfonaminoquinoline Hepcidin Antagonists |
| JP2013075834A (ja) * | 2011-09-29 | 2013-04-25 | Kowa Co | Ｔｌｒ９阻害活性を有するピラゾロピリミジン−７−アミン誘導体 |
| WO2013060881A1 (en) | 2011-10-27 | 2013-05-02 | Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patientenzorg | Pyridopyrimidines and their therapeutic use |
| WO2014086453A1 (en) | 2012-12-07 | 2014-06-12 | Merck Patent Gmbh | Azaheterobicyclic compounds |
| JP6509838B2 (ja) | 2013-06-26 | 2019-05-08 | アッヴィ・インコーポレイテッド | Ｂｔｋ阻害薬としての一級カルボキサミド類 |
| AU2014308616B2 (en) * | 2013-08-23 | 2018-12-06 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
| JP6223563B2 (ja) * | 2013-10-14 | 2017-11-01 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 選択的に置換されたキノリン化合物 |
| CN105636945B (zh) * | 2013-10-14 | 2017-11-17 | 卫材R&D管理有限公司 | 选择性取代的喹啉化合物 |
| CN104557913B (zh) | 2013-10-28 | 2017-02-08 | 上海汇伦生命科技有限公司 | 吡啶并嘧啶类化合物，其制备方法和用途 |
| CN105992766A (zh) | 2013-12-13 | 2016-10-05 | 武田药品工业株式会社 | 作为tlr抑制剂的吡咯并[3,2-c]吡啶衍生物 |
| JP6487921B2 (ja) | 2013-12-17 | 2019-03-20 | ファイザー・インク | ＬＲＲＫ２阻害薬としての新規の３，４−二置換−１Ｈ−ピロロ［２，３−ｂ］ピリジンおよび４，５−二置換−７Ｈ−ピロロ［２，３−ｃ］ピリダジン |
| EP3102580A4 (en) | 2014-02-05 | 2017-07-05 | Stereokem Inc. (USA) | Expedient synthesis of sitagliptin |
| CN104945377A (zh) | 2014-03-24 | 2015-09-30 | 南京明德新药研发股份有限公司 | 作为smo抑制剂的喹啉衍生物 |
| US9938292B2 (en) | 2014-03-24 | 2018-04-10 | Guangdong Zhongsheng Pharmaceutical Co., Ltd | Quinoline derivatives as SMO inhibitors |
| MX377916B (es) | 2014-04-22 | 2025-03-10 | Hoffmann La Roche | Compuestos 4-amino-imidazoquinolina. |
| GB201411236D0 (en) | 2014-06-25 | 2014-08-06 | Takeda Pharmaceutical | Novel compounds |
| RU2719446C2 (ru) | 2014-11-03 | 2020-04-17 | Айомет Фарма Лтд | Фармацевтическое соединение |
| UY36390A (es) * | 2014-11-05 | 2016-06-01 | Flexus Biosciences Inc | Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen |
| MX2017006302A (es) * | 2014-11-13 | 2018-02-16 | Glaxosmithkline Biologicals Sa | Derivados de adenina que son utiles en el tratamiento de enfermedades alergicas u otras afecciones inflamatorias. |
| WO2016087593A1 (en) * | 2014-12-05 | 2016-06-09 | Syngenta Participations Ag | Novel fungicidal quinolinylamidines |
| MA41169A (fr) | 2014-12-17 | 2017-10-24 | Acraf | Composés antibactériens à large spectre d'activité |
| JP2018525345A (ja) | 2015-07-01 | 2018-09-06 | ノースウェスタン ユニバーシティ | 置換キナゾリン化合物及びグルコセレブロシダーゼ活性の調節のためのその使用 |
| WO2017031427A1 (en) | 2015-08-19 | 2017-02-23 | 3-V Biosciences, Inc. | COMPOUNDS AND METHODS FOR INHIBITING mTOR |
| CA3005766A1 (en) * | 2015-12-17 | 2017-06-22 | Merck Patent Gmbh | Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders |
| US20190119236A1 (en) * | 2016-02-23 | 2019-04-25 | Portola Pharmaceuticals, Inc. | Compounds for binding proprotein convertase subtilisin/kexin type 9 (pcsk9) |
| JP7125385B2 (ja) | 2016-08-08 | 2022-08-24 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｔｌｒ７／８アンタゴニストおよびそれらの使用 |
| ES2959782T3 (es) * | 2016-12-20 | 2024-02-28 | Fmc Corp | Oxadiazoles fungicidas |
| US11050028B2 (en) * | 2017-01-24 | 2021-06-29 | Universal Display Corporation | Organic electroluminescent materials and devices |
| EP3655401B1 (en) | 2017-07-18 | 2023-09-06 | Merck Patent GmbH | Tlr7/8 antagonists and uses thereof |
| SG11202005547YA (en) | 2017-12-19 | 2020-07-29 | Merck Patent Gmbh | Tlr7/8 antagonists and uses thereof |
| SG11202100818RA (en) | 2018-07-31 | 2021-02-25 | Merck Patent Gmbh | Tlr7/8 antagonists and uses thereof |
-
2017
- 2017-08-07 JP JP2019507303A patent/JP7125385B2/ja active Active
- 2017-08-07 DK DK17754553.0T patent/DK3497094T3/da active
- 2017-08-07 MX MX2019001096A patent/MX390698B/es unknown
- 2017-08-07 RU RU2019105719A patent/RU2758686C2/ru active
- 2017-08-07 EP EP17754553.0A patent/EP3497094B1/en active Active
- 2017-08-07 WO PCT/US2017/045671 patent/WO2018031434A1/en not_active Ceased
- 2017-08-07 ES ES17754553T patent/ES2944573T3/es active Active
- 2017-08-07 KR KR1020247004013A patent/KR102942565B1/ko active Active
- 2017-08-07 AU AU2017311047A patent/AU2017311047B2/en active Active
- 2017-08-07 SG SG11201900947RA patent/SG11201900947RA/en unknown
- 2017-08-07 KR KR1020197006660A patent/KR102635885B1/ko active Active
- 2017-08-07 CN CN201780049341.XA patent/CN109563075B/zh active Active
- 2017-08-07 EP EP23154971.8A patent/EP4198031A1/en active Pending
- 2017-08-07 US US15/670,068 patent/US10947214B2/en active Active
-
2019
- 2019-02-05 IL IL264676A patent/IL264676B/en unknown
-
2020
- 2020-09-18 US US16/948,432 patent/US11512069B2/en active Active
- 2020-09-21 US US16/948,467 patent/US20210002256A1/en active Pending
-
2024
- 2024-07-24 US US18/782,269 patent/US20240383876A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019527718A5 (https=) | ||
| RU2019105719A (ru) | Антагонисты tlr7/8 и их применение | |
| JP2018537501A5 (https=) | ||
| RU2020123151A (ru) | Антагонисты tlr7/8 и их применение | |
| JP2020537671A5 (https=) | ||
| JP2015511638A5 (https=) | ||
| CA2972014A1 (en) | Fused pyrimidine compounds for the treatment of hiv | |
| RU2019131017A (ru) | Соединения гетероарила в качестве ингибиторов btk и их применение | |
| RU2017101829A (ru) | Пиразоловые соединения в качестве модуляторов fshr и пути их применения | |
| JP2016525075A5 (https=) | ||
| JP2019529484A5 (https=) | ||
| JP2017530959A5 (https=) | ||
| RU2017111200A (ru) | Циклогексилэтилзамещенные диаза- и триаза-трициклические соединения в качестве антагонистов индоламин-2,3-диоксигеназы для лечения рака | |
| JP2014521653A5 (https=) | ||
| JP2015529235A5 (https=) | ||
| RU2015124002A (ru) | Соединения, применяемые в качестве ингибиторов индоламин-2,3-диоксигеназы | |
| JP2016530259A5 (https=) | ||
| RU2017120274A (ru) | Гетероарильные соединения в качестве ингибиторов irak и их применения | |
| JP2011529049A5 (https=) | ||
| JP2017537940A5 (https=) | ||
| JP2016505512A5 (https=) | ||
| JP2017533968A5 (https=) | ||
| JP2017504635A5 (https=) | ||
| RU2013148405A (ru) | Ингибиторы киназ | |
| JP2017524733A5 (https=) |